Shanghai Juncell Therapeutics Co., Ltd. recently celebrated a milestone in its corporate development, completing a Series A financing round at a level of nearly ¥ 100 million. This round was led by Kaitai Capital, followed by Med-Fine Capital, with continued contribution from the existing shareholder Fu Rong Investment, with Haoyue Capital acting as the exclusive financial advisor.

Dr. Huajun Jin, founder of Juncell Therapeutics said: TIL therapy is a promising but challenging strategy for personalized treatment of solid tumors. After nearly a year of efforts, we have made great progress in technologies such as TILs  enrichment culture and T cell gene modification based on non-viral vector, which has brought the product into the non-registered clinical study stage. In addition, the growing team and the completed GMP production workshop have laid a solid foundation for the steady and healthy development of the company. We are honored to have completed the Series A round within a short period of time, with the favor of famous biomedical funds such as Kaitai Capital and Med-Fine Capital, the continuous support from our existing shareholder Fu Rong Capital and Ariza Seed, and we also thank Haoyue Capital for their continued professional help! We will focus on TIL therapies and accelerate the development of new TIL drugs.